Physician profile
Samuel P Smith
NPI 1295802700
$18,766.58
in general payments reported to CMS, 2019-2025
16 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,668 · 2020: $2,035 · 2021: $3,362 · 2022: $3,179 · 2023: $2,205 · 2024: $1,891 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,522.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $6,686.66 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,728.17 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $2,574.07 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $2,312.32 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,750.62 | 2019-2023 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,199.46 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $484.83 | 2019-2021 | |
| Allergan, INC. | $263.67 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $210.00 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $122.25 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $121.02 | 2021 | |
| Lundbeck LLC | $118.63 | 2019-2021 | |
| Almatica Pharma LLC | $68.46 | 2023-2024 | Loreev Xr |
| Noven Therapeutics, LLC | $56.02 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.63 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.